Thus, PBMCs from 8 CLL patients were cultured in the presence of lenalidomide or IL-2 and the anti-ILT2 blocking antibody for 7 days and the expression of the immune activation marker CD69 was analyzed on NK cells by flow cytometry. The gene discussed is LILRB1; the disease is B-cell chronic lymphocytic leukemia.